E-Poster Display Session Eposter Display
24.03.2021 08:00 - 20:00 e-Poster Display Session ePoster Display 08:00 - 08:00 Tumour biology and pathology S. Not Yet Confirmed, Johns Hopkins Kimmel Cancer Center, Baltimore, US 08:00 - 08:00 1P - Real-world Frequency of Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (Exon20ins) Mutations by Site of Insertion S. Viteri1, J. Bauml2, L. Bazhenova3, S.-H.I. Ou4, N. Girard5, M. Schaffer6, J. Rose6, J. Curtin6, J. Karkera6, P. Mahadevia7, A. Minchom8, 1Instituto Oncológico Dr Rosell, Centro Médico Teknon, Grupo QuironSalud, Barcelona, ES, 2Perelman School of Medicine at the University of Pennsylvania, Philadelphia, US, 3Moores Cancer Center - UC San Diego Health, La Jolla, US, 4University of California Irvine, Orange, US, 5Institut Curie, Paris, FR, 6Janssen R&D, Spring House, US, 7Janssen Pharmaceuticals, Raritan, US, 8The Royal Marsden Hospital - NHS Foundation Trust, London, GB 08:00 - 08:00 2P - Role of neutrophil-to-lymphocyte ratio (NLR) in the outcome of NSCLC EGFR mutated S. Tolu1, G. Saba2, V. Impera1, D. Spanu2, N. Liscia1, G. Pinna2, A. Pireddu1, L. 2, 2, 2, 2, 2, 2, 2, Demurtas E. Lai F. Manca C. Madeddu A. Gabizon G. Astara M. Scartozzi 1University of Cagliari - Sapienza Università di Roma, Monserrato (CA), IT, 2University of Cagliari, Monserrato (CA), IT 08:00 - 08:00 3P - AZ12756122, a novel Fatty Acid Synthase (FASN) inhibitor, reduces resistance properties in Gefitinib- and Osimertinib resistant EGFR-mutated non- small cell lung cancer models E. Polonio1, S. Palomeras1, R. Porta-Balanya2, J. Bosch-Barrera2, C. Vásquez3, J. Ciurana1, S.
[Show full text]